Oncoinvent reports positive 18-month Phase 1 data for Radspherin in ovarian cancer trial

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
The Food and Beverage Association of Ghana (FABAG) Assures of Falling Food...
African Union Commission (AUC) Chairperson received H.E. Dr...
Algeria: Foreign Affairs ministry celebrates National Memory...
African Union Commission (AUC) Chairperson received H.E. Mr...
Modern Image Co...
Algeria: Foreign Affairs ministry celebrates National Memory...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Oncoinvent reports positive 18-month Phase 1 data for Radspherin in ovarian cancer trial

Clinical-stage radiopharmaceutical company Oncoinvent ASA (Euronext Growth Oslo:ONCIN) on Monday announced updated 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal...

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search